Results 21 to 30 of about 13,238 (216)

Reactogenicity in PLWH.

open access: yes, 2022
Reactogenicity in PLWH.
Wouter F. W. Bierman (4164670)   +33 more
core   +1 more source

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study

open access: yesBMC Infectious Diseases, 2022
Background Due to safety signals after vaccination with COVID-19 vector vaccines, several states recommended to complete the primary immunization series in individuals having received one dose of ChAdOx1 (AstraZeneca) with an mRNA vaccine.
Lisette Warkentin   +8 more
doaj   +1 more source

Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

open access: yesVaccines, 2021
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response.
Jorge Hernández-Bello   +8 more
doaj   +1 more source

Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study

open access: yesCOVID, 2022
The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical trials. However, the real-world efficacy often differed.
Sri Masyeni   +7 more
openaire   +1 more source

Rubella Vaccine – How ‘Reactogenic’ is it?

open access: yesJournal of International Medical Research, 1986
Girls (231) aged 11—13 years were allocated at random to receive one of two RA27/3 rubella vaccines. A high incidence of minor and self-limiting side-effects were found by intensive follow-up. No difference in reactogenicity could be found between vaccines from the Institut Merieux and Wellcome.
G V, Griffin, K A, Bryett
openaire   +2 more sources

Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers

open access: yesVaccines, 2022
At the start of the SARS-CoV-2 pandemic, healthcare workers had an increased risk of acquiring coronavirus disease (COVID)-19. As tertiary care hospitals are critical for the treatment of severely ill patients, the University Hospital Erlangen offered ...
Valentin Niekrens   +7 more
doaj   +1 more source

Typhoid VI: A Less Reactogenic Vaccine

open access: yesJournal of International Medical Research, 1992
A typhoid vaccine derived from the purified Vi capsular polysaccharide (CPS) antigen of Salmonella typhi was compared with a heat-killed whole-cell typhoid vaccine in 637 healthy male volunteers. The individuals were placed in three groups: group 1 received two doses of heat-killed whole-cell typhoid vaccine, at an interval of 28 days; group 2 received
N S, Cumberland   +4 more
openaire   +2 more sources

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

open access: yesHuman Vaccines & Immunotherapeutics, 2023
We conducted a dose-finding phase 2 study of the HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in two cohorts of children, 6–≤12 months and 1–≤4 years of age (N = 120 per cohort), in Panama and Colombia (ClinicalTrials.gov ...
Pio López   +8 more
doaj   +1 more source

Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

open access: yesVaccines, 2021
Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as
Alborz Rahmani   +14 more
doaj   +1 more source

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females

open access: yesHuman Vaccines & Immunotherapeutics, 2023
As global supply is still inadequate to address the worldwide requirements for HPV vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine.
Li-Wei Shi   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy